Dr Roy Herbst talks to ecancer at ESMO 2018 about the latest from the KEYNOTE-10 trial for non small cell lung cancer. He discussed the latest data from this trial, noting the improved 3 year survival rate with patients expressing higher levels of...
Original Article: KEYNOTE 10: Pembrolizumab vs docetaxel for NSCLC